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| INTRODUCTION
Prophylaxis for severe hemophilia is more effective than on-demand therapy for the treatment of severe hemophilia, 1 but there is no agreed-upon optimal prophylaxis regimen. 2, 3 The Canadian Hemophilia
Prophylaxis Study (CHPS) group previously examined the cost-effectiveness of a tailored, frequency-escalated prophylaxis regimen. 4 This form of prophylaxis is generally less costly than full-dose prophylaxis.
5
Despite the growing practice of prescribing prophylaxis, adherence to the prophylaxis regimen is required for benefit, regardless of which prophylaxis regimen is used. In severe hemophilia, sustained adherence to factor replacement therapy is required to prevent recurrent spontaneous bleeding into muscles and joints due to the relatively short halflife of standard plasma-derived or recombinant clotting factor products.
6
A global definition of adherence, as it relates to medication, does not exist. 7, 8 The World Health Organization has adopted a broad definition for adherence, calling it the "extent to which a person's behavior … corresponds with agreed recommendations from a health care provider." 9 This broad definition is because standards for adequate adherence are highly disease dependent. For example,
HIV-infected individuals with medication adherence levels <95% experience a poor response to treatment, whereas individuals with conditions such as diabetes or asthma can achieve satisfactory symptom control at adherence rates of 40% to 60%.
9
For hemophilia, there is no evidence-based threshold for what should be considered adequate adherence to a recommended prophylaxis regimen. There is, however, evidence to suggest that the threshold should be high; previous work has shown that even limited nonadherence can result in irreversible joint damage.
10
Unfortunately, high levels of adherence are often difficult to maintain, especially for the treatment of chronic conditions. 9 Factor VIII (FVIII) and IX (FIX) replacement therapy, as is currently prescribed, involves regular intravenous infusions of clotting factor, which can be challenging for reasons that include needle aversion and difficult venous access, particularly in very young boys started on programs of primary prophylaxis.
11,12
The CHPS was a single-arm, multicenter prospective study designed to investigate the efficacy of a tailored, frequency-escalated, primary prophylaxis regimen. 13 This current substudy had 2 objectives: first, to describe the treatment adherence rates for CHPS participants and determine if the frequency-escalated approach resulted in better adherence than is reported in the literature and second, to examine the relationship between treatment adherence and bleeding episodes. Specifically, we sought to confirm the theorized strong relationship between adherence and bleeding.
| METHODS

| Study design
The CHPS was an inception cohort of 56 young boys with severe hemophilia A, defined by a circulating FVIII level of <2%.
Detailed descriptions of the study design have been previously reported. 13, 14 For the current analysis, we assessed the factor infusion and bleeding logs of all 56 boys on study from 1997 to 2013.
Six subjects were lost to follow-up over the course of the 15-year follow-up period.
| Inclusion and exclusion criteria
The detailed inclusion and exclusion criteria of the CHPS have been previously reported. 13, 14 Briefly, subjects were between 12 and 30 months of age at the time of enrollment, with normal joints on radiologic examination, no clinically significant bleeding history, and no present or past history of an FVIII inhibitor. Subjects were not enrolled if they had ≥3 bleeds into any 1 joint, a history of inhibitor, or a competing disease such as hepatitis C.
| Tailored, frequency-escalated prophylaxis protocol
Subjects enrolled in the CHPS were treated with 3 treatment steps and specific criteria for escalation ( 
| Measuring adherence
Adherence to the prescribed prophylaxis regimen was calculated on a weekly basis. A given week was considered adherent if the subject completed all of their infusions as per their prescribed step on the protocol; infusions given beyond the number required were not included when determining adherence to prophylaxis so that no patient could have an adherence rate of >100%. Similar rates were also calculated for adherence to the prescribed enhanced episodic treatment schedule. This information was collected from each subject's infusion log.
Bleeding rates were collected from the subject's self-or proxy-reported bleeding logs. Bleeding and treatment for bleeding were recorded by parents, guardians, or the participants themselves and confirmed by study personnel at each study visit (every 3 months for the first 5 years of the study, then every 6 months). The bleeding episodes were classified by study staff as index hemarthroses (ie, bleeds into ankles, elbows, or knees), other hemarthroses, muscle bleeds, superficial bleeds, mucosal bleeds, or life-threatening bleeds (eg, intracranial or airway bleeding).
| Outcome
The primary outcome was adherence to the prescribed prophylaxis regimen and how the adherence in our cohort compared to previously reported adherence rates. Secondary outcomes included adherence to the enhanced episodic therapy protocol and bleeding rates.
| Literature review
We conducted a search of the literature in MEDLINE, using the reported. Population characteristics, reported definitions of adherence, adherence rates, and any other relevant information on how the authors described adherence were abstracted and qualitatively summarized.
TA B L E 1 Dose and escalation criteria for the tailored, frequency-escalated, prophylaxis approach used in the CHPS
Dose regimen Escalation criteria
Step 1:50 IU/kg a 1×/wk ≥3 bleeds into any single joint over a consecutive 3-mo period; or
Step 2:30 IU/kg a 2×/wk ≥4 significant soft tissue or joint bleeds (into any number of joints) over a consecutive 3-mo period; or
Step 3:25 IU/kg a , alternate days, minimum 3×/wk ≥5 bleeds into any single joint while on the same dose of factor therapy a Rounded to the nearest vial size.
| Statistical analysis
We used descriptive statistics (median, range of values [ROV] ) to describe the cohort and their adherence rates. We calculated 95% confidence intervals (CIs) on reported adherence data found in the literature review using either the published median and sample size, or mean, standard deviation, and sample size. Due to the variability in the way adherence was defined and reported, we compared our rates and confidence interval bands qualitatively to those reported in the literature.
The association between having a central venous access device (CVAD) and adherence was determined using a generalized linear mixed-effects model, with a logistic link function and random intercept, adjusting for the time spent in each step of the protocol.
The relationship between adherence and bleeding was determined through a recurrent event analysis using a Cox proportional hazards model with robust standard errors, controlling for age and step of the protocol. We defined each risk period as Monday through Sunday of a given week to infer whether a patient would have bled during that week based on their average weekly adherence to the prescribed prophylaxis regimen over the previous 12 weeks. We chose to look at adherence for the 12 weeks prior to the event week to provide a stable representation of adherence over time, and because the infusion diaries and bleed logs were collected every 12 weeks for the first 5 years of the study. We performed a sensitivity analysis using varying time frames for average adherence (over the preceding 2 and 6 weeks) to test the robustness of the relationship. We included all available data in our analysis, including data from subjects who were lost to follow-up.
We performed a sensitivity analysis of our primary model using 4 scenarios for weeks with missing bleed or adherence data. For these analyses, we separately assumed that weeks with missing adherence data were either all adherent or all nonadherent (ie, all 1 or 0), and that weeks with missing bleed data were either all bleeding weeks or all nonbleeding weeks (ie, all 1 or 0).
We also performed an exploratory analysis using multiple linear regression to investigate which factors might be predictive of end-of-study joint damage as determined by the magnetic resonance imaging (MRI) 17-point International Prophylaxis Study Group (IPSG) scores or the Hemophilia Joint Health Scores (HJHS) (both previously described 13 ). The covariates that were considered in this analysis were overall adherence to prophylaxis, adherence to the enhanced episodic therapy following bleeds, annualized index joint bleeding rate, and the age at first joint bleed.
We conducted all analyses using R version 3.5.0 15 .
| RESULTS
| Sample
Fifty-six boys with severe hemophilia A were followed as part of the CHPS cohort for a median (ROV) of 10.2 (0.2-16.1) years (Table 2 ).
This represents a median (ROV) of 506 (10-841) weeks of infusion diaries and bleeding logs. There was a median (ROV) of 3.9% (0%-27.6%) of weeks missing per subject.
| Adherence
In our cohort, the overall median (ROV) adherence with prophylaxis therapy protocol (ie, following an index joint or muscle bleed [see above]) was 47.1% (0%-100%) per subject.
Our literature search for reported adherence rates identified 232
articles. Abstracts and titles were reviewed by one of the authors (SD), and 15 manuscripts were retrieved that reported adherence rates for a cohort that included pediatric patients. Results are summarized in Table 3 ; where the cohort included both pediatric and adult populations, only the pediatric results are presented.
In the articles retrieved, there was a high degree of variability in how adherence was defined and reported, which made it impossible to combine studies for meta-analysis. However, we did find that our cohort, at a median 92.9% (95% CI, 86.2%-99.6%) adherent weeks per subject, had higher adherence while on step 1 of our tailored frequency-escalated protocol than any other reported adherence rates, whether objective or subjective. This was higher than the upper confidence bounds reported in 7 of 10 manuscripts where a 95% CI could be calculated from the published data. Our overall adherence rate of 85.7% (95% CI, 76.5%-94.9%) adherent weeks was also either within (for 5/10 studies) or above (for 5/10 studies) the confidence bounds of the other reported adherence rates.
| Bleeding
Adherence was strongly associated with a decreased risk of bleeding, after accounting for age (Table 4) . A 10% increase in the absolute adherence rate over any 12-week period was associated with a 15% reduction in bleeding rate (hazard ratio [HR] 0.85; 95% CI, 0.81-0.90). The observed effect diminished slightly as the prophylaxis step increased, but the association remained strong and highly significant. Our sensitivity analysis of varying adherence time frames showed, in fact, a stronger relationship between adherence and bleeding than we observed when analyzing the average adherence over 12 weeks (as the adherence time frame got smaller, the HR decreased as well; Table S1 ). Our sensitivity analysis, to account for missing data, showed similar HRs (Table S2) .
| Joint health
The only statistically significant predictive model for end-of-study 
| DISCUSSION
Our results show that adherence rates for subjects on a tailored, frequency-escalated primary prophylaxis regimen were high. Our median adherence level of over 85% is consistent with other reported cohorts, including a survey of 6 European countries that reported adherence rates in the 80% to 87% range 16 and an Australian summary of real-world prophylaxis use that reported a majority of patients in the "optimal" adherence range of 75% to 125% of expected clotting factor concentrate use.
17 However, the median adherence level from step 1 of our prophylaxis regimen of almost 93% was higher than has previously been re- 
13
The subjects who had a CVAD for some period of time during the study demonstrated increased adherence during the time when infusions were administered via the CVAD compared to the time when infusions were given via peripheral venipuncture. This may be because accessing a CVAD for a home-infusion is easier for parents or caregivers, and difficult peripheral venous access may lead to multiple attempts and ultimately missed infusions. Additionally, in many cases, a parent or caregiver was the one giving infusions via a CVAD, whereas peripheral venous infusions may have been more likely to be self-administered, especially as the boys got older, which may account for the lower adherence.
We found that adherence to the prophylaxis regimen in the previous 12 weeks was associated with a decreased risk of bleeding at any given time. The effect was strongest for subjects infusing once weekly (ie, those on step 1) and decreased slightly as the frequency of infusions increased. This was not surprising, as adherence is most important when receiving only 1 infusion/week, as missing that single infusion would leave a patient unprotected for several days, compared to ≥2 infusions/week where missing TA B L E 3 Summary of previously reported adherence definitions and rates for pediatric cohorts of subjects with either hemophilia A or B Our cohort of patients had very high adherence rates and very low bleeding rates. It is possible that the association between adherence and bleeding seen in our cohort would be even stronger for a group of patients where adherence was lower, and there would likely have been more bleeding events. Although there were some missing data from the subjects' logs, the sensitivity analysis showed that the effect of the missing data was negligible.
It is possible that the cohort of patients who enrolled in the study may have been more likely to be adherent to their therapy than the general hemophilia population. For the CHPS, we excluded patients and families thought to be nonadherent based on the assessment of the local investigator at each site. During the recruitment period, 14 patients were excluded for this reason. While no specific strategies were used to encourage adherence as part of the study protocol, this exclusion criterion may have affected our adherence rates. However, our results showed a correlation between bleeding and adherence, and had we had more patients whose adherence was lower, we would have seen a larger effect.
Finally, one of our study patients was on study for only a very short period of time. Removing this subject did not affect any of the results (data not shown), so this patient was left in, as we included all patients with available data in all analyses.
| CONCLUSION
Overall, the adherence rates for subjects on tailored frequencyescalated primary prophylaxis were high, and starting the cohort on once-weekly infusions resulted in adequate factor coverage while maintaining an above-average adherence level. Higher adherence rates were associated with a marked reduction in risk of bleeding at any given time. Moreover, adherence likely plays a definable role in determining long-term joint outcomes in patients with severe hemophilia. 
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TA B L E 4 Relationship between adherence and risk of bleeding
Step of protocol Hazard ratio 95% CI
Step 1 0.78 0.70-0.85
Step 2 0.83 0.78-0.88
Step 3 Note: The hazard ratio represents the reduction in bleeding rate associated with 10% (additive) increase in adherence over any given 12-wk period. The hazard ratios show a reduction of the bleeding rate, which is true across all protocol treatment steps, but diminished as prophylaxis step increased.
